S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
2 Must-Have Silicon Companies That Don't Make Microchips
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Small Caps That Have Priced In A Hard Landing For Big Upside
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
AI Boosts Duolingo As Company Posts First Profit
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
2 Must-Have Silicon Companies That Don't Make Microchips
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Small Caps That Have Priced In A Hard Landing For Big Upside
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
AI Boosts Duolingo As Company Posts First Profit
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
2 Must-Have Silicon Companies That Don't Make Microchips
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Small Caps That Have Priced In A Hard Landing For Big Upside
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
AI Boosts Duolingo As Company Posts First Profit
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
2 Must-Have Silicon Companies That Don't Make Microchips
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Small Caps That Have Priced In A Hard Landing For Big Upside
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
AI Boosts Duolingo As Company Posts First Profit
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
NASDAQ:BIS

ProShares UltraShort Nasdaq Biotechnology (BIS) Price, Holdings, & News

$22.59
+0.16 (+0.71%)
(As of 09/25/2023 ET)
Compare
Today's Range
$22.49
▼
$22.69
50-Day Range
$19.99
▼
$22.59
52-Week Range
$17.88
▼
$27.42
Volume
1,131 shs
Average Volume
8,979 shs
Market Capitalization
$5.65 million
Assets Under Management
$4.92 million
Dividend Yield
0.62%
Net Expense Ratio
0.95%
ProfileChartDividendHeadlinesHoldingsOptions ChainShort InterestSocial Media
BIS stock logo

About ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.

BIS Price History

BIS ETF News Headlines

May 13, 2023 | morningstar.com
ProFunds UltraShort NASDAQ-100 Svc
May 9, 2023 | marketwatch.com
Trading Proshares Ultrashort S&p500 $SDS With Integrated Risk Controls
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
March 12, 2023 | morningstar.com
ProFunds UltraShort NASDAQ-100 Inv
January 29, 2023 | benzinga.com
Trinity Biotech Stock (NASDAQ:TRIB), Quotes and News Summary
January 26, 2023 | cnbc.com
NASDAQ Biotechnology Index .NBI : NASDAQ
November 12, 2022 | seekingalpha.com
BIB ProShares Trust - ProShares Ultra Nasdaq Biotechnology
September 19, 2022 | nasdaq.com
Five Myths about Nasdaq Indexes
September 26, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
September 14, 2022 | thestreet.com
Allergan, Tesla and iShares Nasdaq Biotechnology: Doug Kass' Views
See More Headlines
Receive BIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProShares UltraShort Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
ProShares
Fund Name
ProShares UltraShort Nasdaq Biotechnology
Tax Classification
Regulated Investment Company
Stock Exchange
NASDAQ
Current Symbol
NASDAQ:BIS
Inception Date
4/6/2010
Fund Manager
Michael Neches, Tarak Dave
Web
www.proshares.com
Phone
+1-240-4976400

Fund Focus

Asset Class
Equity
Benchmark
Nasdaq Biotech Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
15

Fund Statistics

Assets Under Management
$4.92 million
Average Daily Volume
$22,534.70
Discount/Premium
0.02%
Leveraged
-2.00

Administrator, Advisor and Custodian

Administrator
J.P. Morgan Investor Services Co.
Advisor
ProShare Advisors LLC
Custodian
JPMorgan Chase Bank, N.A.
Distributor
SEI Investments Distribution Co.
Transfer Agent
JPMorgan Chase Bank, N.A.
Trustee
N/A
Lead Market Maker
IMC

Options

Optionable
N/A
Short Interest
16,900 shs

Miscellaneous

Outstanding Shares
250,000
Beta
-1.41
Creation Unit
50,000
Creation Fee
$250.00
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

ProShares UltraShort Nasdaq Biotechnology Expenses

TypeBISHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.75%0.57%0.53%0.47%0.50%
Other Expenses0.80%0.40%0.52%0.29%0.57%
Total Expense1.55%0.72%0.69%0.56%0.69%
Fee Waiver-0.60%-0.51%-0.55%-0.22%-0.59%
Net Expense0.95%0.61%0.59%0.51%0.57%

ProShares UltraShort Nasdaq Biotechnology (BIS) Holdings

Top 7 BIS Holdings

  • NET OTHER ASSETS (LIABILITIES)
    Holding Weight: 0.00%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG
    Holding Weight: -4.40%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP MORGAN STANLEY & CO. INTERNATIONAL PLC
    Holding Weight: -20.60%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA
    Holding Weight: -30.11%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA
    Holding Weight: -31.76%
  • NASDAQ BIO INDEX SWAP BNP
    Holding Weight: -34.51%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE
    Holding Weight: -78.77%
Full Holdings Details













BIS ETF - Frequently Asked Questions

How have BIS shares performed in 2023?

ProShares UltraShort Nasdaq Biotechnology's stock was trading at $19.64 at the beginning of the year. Since then, BIS stock has increased by 15.0% and is now trading at $22.59.
View the best growth stocks for 2023 here.

Are investors shorting ProShares UltraShort Nasdaq Biotechnology?

ProShares UltraShort Nasdaq Biotechnology saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 16,900 shares, an increase of 59.4% from the August 15th total of 10,600 shares. Based on an average trading volume of 3,400 shares, the days-to-cover ratio is currently 5.0 days.
View ProShares UltraShort Nasdaq Biotechnology's Short Interest.

How often does ProShares UltraShort Nasdaq Biotechnology pay dividends? What is the dividend yield for ProShares UltraShort Nasdaq Biotechnology?

ProShares UltraShort Nasdaq Biotechnology declared a quarterly dividend on Tuesday, September 19th. Shareholders of record on Thursday, September 21st will be given a dividend of $0.1187 per share on Wednesday, September 27th. This represents a $0.47 dividend on an annualized basis and a yield of 2.10%. The ex-dividend date of this dividend is Wednesday, September 20th.
Read our dividend analysis for BIS.

What does BIS invest in?

ProShares UltraShort Nasdaq Biotechnology is a equity fund issued by ProShares. BIS focuses on health care investments and follows the Nasdaq Biotech Index. The fund's investments total to approximately $4.92 million assets under management.

What is the management fee for ProShares UltraShort Nasdaq Biotechnology?

ProShares UltraShort Nasdaq Biotechnology's management fee is 0.75% and has other expenses of 0.80%. However, BIS has a fee waiver of -0.60% to reimburse the expenses. The net expense ratio for BIS is 0.95%.

When did ProShares UltraShort Nasdaq Biotechnology's stock split?

Shares of ProShares UltraShort Nasdaq Biotechnology reverse split on the morning of Tuesday, August 18th 2020. The 1-4 reverse split was announced on Tuesday, August 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 17th 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of ProShares UltraShort Nasdaq Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProShares UltraShort Nasdaq Biotechnology investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Intel (INTC), Quest Diagnostics (DGX), Micron Technology (MU), Pfizer (PFE), Cidara Therapeutics (CDTX) and Vertex Pharmaceuticals (VRTX).

What is ProShares UltraShort Nasdaq Biotechnology's stock symbol?

ProShares UltraShort Nasdaq Biotechnology trades on the NASDAQ under the ticker symbol "BIS."

Who are ProShares UltraShort Nasdaq Biotechnology's major shareholders?

ProShares UltraShort Nasdaq Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include Tower Research Capital LLC TRC (3.31%) and Citadel Advisors LLC (0.00%).
View institutional ownership trends.

How do I buy shares of ProShares UltraShort Nasdaq Biotechnology?

Shares of BIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProShares UltraShort Nasdaq Biotechnology's stock price today?

One share of BIS stock can currently be purchased for approximately $22.59.

How much money does ProShares UltraShort Nasdaq Biotechnology make?

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) has a market capitalization of $5.65 million.

How can I contact ProShares UltraShort Nasdaq Biotechnology?

ProShares UltraShort Nasdaq Biotechnology's mailing address is SUITE 1000, 7501 WISCONSIN AVENUE, Bethesda, MD 20814, United States. The official website for the company is www.proshares.com. The company can be reached via phone at +1-240-4976400.

This page (NASDAQ:BIS) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -